Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

被引：10

作者：

Yoshino, Maki ^{[1
]}

Ishihara, Hiroki ^{[1
]}

Nemoto, Yuki ^{[2
,3
]}

Nakamura, Kazutaka ^{[2
,4
]}

Nishimura, Koichi ^{[1
]}

Tachibana, Hidekazu ^{[5
]}

Fukuda, Hironori ^{[2
]}

Toki, Daisuke ^{[1
]}

Yoshida, Kazuhiko ^{[2
]}

Kobayashi, Hirohito ^{[1
]}

Iizuka, Junpei ^{[2
]}

Shimmura, Hiroaki ^{[4
]}

Hashimoto, Yasunobu ^{[3
]}

Tanabe, Kazunari ^{[2
]}

Kondo, Tsunenori ^{[1
]}

Takagi, Toshio ^{[2
]}

机构：

[1] Tokyo Womens Med Univ, Dept Urol, Adachi Med Ctr, Tokyo, Japan

[2] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[3] Saiseikai Kawaguchi Gen Hosp, Dept Urol, Kawaguchi, Saitama, Japan

[4] Jyoban Hosp, Dept Urol, Iwaki, Fukushima, Japan

[5] Saiseikai Kurihashi Hosp, Dept Urol, Saitama, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 52卷 / 10期

关键词：

immunotherapy; PD-1; CTLA-4; cytoreductive nephrectomy; systemic therapy; SUNITINIB;

D O I：

10.1093/jjco/hyac099

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cytoreductive nephrectomy which deferred to nivolumab plus ipilimumab immunotherapy has the potential therapeutic role for the patients with synchronous mRCC. Objectives To explore the therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Patients and methods Forty-one patients with synchronous metastatic renal cell carcinoma who received nivolumab plus ipilimumab as first-line systemic therapy at our affiliated institutions were retrospectively evaluated. We focused on the prognosis, including tumor responses in primary kidney and metastatic lesions in patients treated with deferred cytoreductive nephrectomy. In addition, the overall survival according to nephrectomy status (i.e. deferred cytoreductive nephrectomy vs. upfront cytoreductive nephrectomy vs. without cytoreductive nephrectomy) was compared. Results During a median follow-up period of 12.0 months, seven (30%) patients received deferred cytoreductive nephrectomy at a median time of 10.4 months after nivolumab plus ipilimumab initiation. All the patients showed tumor shrinkage in their primary kidney lesions, including six (86%) patients with >= 30% of shrinkage. Metastatic lesions were also shrunk by >= 30% in six (86%) patients, including two (29%) obtaining complete response. At the last time of follow-up, three (43%) patients were disease-free. The overall survival rate after nivolumab plus ipilimumab initiation tended to be higher in patients with deferred cytoreductive nephrectomy compared with those with upfront cytoreductive nephrectomy (1-year survival rate: 100% vs. 72.4%, P = 0.0587) and those without cytoreductive nephrectomy (vs. 58.2%, P = 0.0613). Conclusions The present retrospective data showed that deferred cytoreductive nephrectomy had the potential to exert a therapeutic effect in a subset of patients who obtained favorable tumor responses to nivolumab plus ipilimumab for a certain period. Prospective randomized clinical trials are needed to confirm the prognostic impact of deferred cytoreductive nephrectomy after frontline immunotherapy in synchronous metastatic renal cell carcinoma.

引用

页码：1208 / 1214

页数：7

共 20 条

[1] First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial [J].

Albiges, Laurence ;

Tannir, Nizar M. ;

Burotto, Mauricio ;

McDermott, David ;

Plimack, Elizabeth R. ;

Barthelemy, Philippe ;

Porta, Camillo ;

Powles, Thomas ;

Donskov, Frede ;

George, Saby ;

Kollmannsberger, Christian K. ;

Gurney, Howard ;

Grimm, Marc-Oliver ;

Tomita, Yoshihiko ;

Castellano, Daniel ;

Rini, Brian, I ;

Choueiri, Toni K. ;

Leung, David ;

Saggi, Shruti Shally ;

Lee, Chung-Wei ;

McHenry, M. Brent ;

Motzer, Robert J. .

EUROPEAN UROLOGY, 2022, 81 (03) :266-271

[2] Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial [J].

Bex, Axel ;

Mulders, Peter ;

Jewett, Michael ;

Wagstaff, John ;

van Thienen, Johannes V. ;

Blank, Christian U. ;

van Velthoven, Roland ;

Laguna, Maria del Pilar ;

Wood, Lori ;

van Melick, Harm H. E. ;

Aarts, Maureen J. ;

Lattouf, J. B. ;

Powles, Thomas ;

de Jong, Igle Jan ;

Rottey, Sylvie ;

Tombal, Bertrand ;

Marreaud, Sandrine ;

Collette, Sandra ;

Collette, Laurence ;

Haanen, John .

JAMA ONCOLOGY, 2019, 5 (02) :164-170

[3] Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma [J].

Bhindi, Bimal ;

Graham, Jeffrey ;

Wells, J. Connor ;

Bakouny, Ziad ;

Donskov, Frede ;

Fraccon, Anna ;

Pasini, Felice ;

Lee, Jae Lyun ;

Basappa, Naveen S. ;

Hansen, Aaron ;

Kollmannsberger, Christian K. ;

Kanesvaran, Ravindran ;

Yuasa, Takeshi ;

Ernst, D. Scott ;

Srinivas, Sandy ;

Rini, Brian, I ;

Bowman, Isaac ;

Pal, Sumanta K. ;

Choueiri, Toni K. ;

Heng, Daniel Y. C. .

EUROPEAN UROLOGY, 2020, 78 (04) :615-623

[4] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[5] The Feasibility and safety of surgery in Patients receiving immune checkpoint inhibitors: a retrospective study [J].

Elias, Alexandra W. ;

Kasi, Pashtoon M. ;

Stauffer, John A. ;

Thiel, David D. ;

Colibaseanu, Dorin T. ;

Mody, Kabir ;

Joseph, Richard W. ;

Bagaria, Sanjay P. .

FRONTIERS IN ONCOLOGY, 2017, 7

[6] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Porta, C. ;

Schmidinger, M. ;

Rioux-Leclercq, N. ;

Bex, A. ;

Khoo, V. ;

Grunwald, V. ;

Gillessen, S. ;

Horwich, A. .

ANNALS OF ONCOLOGY, 2019, 30 (05) :706-720

[7] Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer [J].

Flanigan, RC ;

Salmon, SE ;

Blumenstein, BA ;

Bearman, SI ;

Roy, V ;

McGrath, PC ;

Caton, JR ;

Munshi, N ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1655-1659

[8] Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study [J].

Ishihara, Hiroki ;

Takagi, Toshio ;

Yoshida, Kazuhiko ;

Hashimoto, Yasunobu ;

Kondo, Tsunenori ;

Tanabe, Kazunari .

INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (10) :1075-1076

[9] Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma [J].

Kikuchi, Hiroshi ;

Osawa, Takahiro ;

Matsumoto, Ryuji ;

Abe, Takashige ;

Maruyama, Satoru ;

Harabayashi, Toru ;

Miyata, Haruka ;

Kashiwagi, Akira ;

Ikeshiro, Suguru ;

Sazawa, Ataru ;

Fukui, Riyo ;

Morita, Ken ;

Takeuchi, Ichiro ;

Hori, Kanta ;

Yamashita, Noboru ;

Minami, Keita ;

Mochizuki, Tango ;

Murai, Sachiyo ;

Shinohara, Nobuo .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (01) :13.e19-13.e27

[10] European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update [J].

Ljungberg, Borje ;

Albiges, Laurance ;

Abu-Ghanem, Yasmin ;

Bensalan, Karim ;

Dabestani, Saeed ;

Montes, Sergio Fernandez-Pello ;

Giles, Rachel H. ;

Hofmann, Fabian ;

Hora, Milan ;

Kuczyk, Markus A. ;

Kuusk, Teele ;

Lam, Thomas B. ;

Marconi, Lorenzo ;

Merseburger, Axel S. ;

Powles, Thomas ;

Staehler, Michael ;

Tahbaz, Rana ;

Volpe, Alessandro ;

Bex, Axel .

EUROPEAN UROLOGY, 2019, 75 (05) :799-810

← 1 2 →